Picard Medical, Inc.
No enriched coverage for $PMI in the last 7 days.
No SEC Form 4 filings for $PMI in the last 30 days.
See all $PMI insider activity →Kuehn Law is investigating Picard Medical Inc. (PMI) officers and directors for alleged fiduciary breaches. A lawsuit claims insiders misled shareholders about a stock promotion scheme, offshore share dumping, and omissions in public statements. Shareholders who bought before September 2, 2025, are encouraged to contact the firm.
Picard Medical's stock fell 14.5% in morning trading, reversing recent gains. The company has relied on equity issuances for funding, has a thin cash position, and lacks near-term catalysts. Broader market declines also contributed to the drop. The company is working to meet NYSE listing standards.
Picard Medical Inc. (PMI) shares rose 27% after Q2 2026 revenue of $2.954M beat estimates by 90.58%, up 38.62% YoY. Despite a loss of $(3.05) per share, investors focused on top-line growth and improved gross margins. The company is investing in R&D for its next-gen Emperor Total Artificial Heart, presenting new data at conferences. PMI completed a 1-for-50 reverse stock split in July 2026 to regain NYSE compliance.
Recent PMI coverage spans earnings, market movers and regulation.
Potential legal liability and shareholder lawsuits could depress PMI stock price.
Near-term downside bias as traders unwind speculative gains and focus on ongoing dilutive equity funding needs.
Strong top‑line beat sparked a sharp price rally, but widening net loss tempers upside.
Moderate pre‑market gain indicates bullish sentiment.
Positive earnings beat with strong revenue growth.
AlphAI scores every news story that mentions PMI with an AI model for sentiment and relevance, and aggregates insider trades from Picard Medical, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Kuehn Law is investigating Picard Medical Inc. (PMI) officers and directors for alleged fiduciary breaches. A lawsuit claims insiders misled shareholders about a stock promotion scheme, offshore share dumping, and omissions in public statements. Shareholders who bought before September 2, 2025, are encouraged to contact the firm.
1 min readPicard Medical's stock fell 14.5% in morning trading, reversing recent gains. The company has relied on equity issuances for funding, has a thin cash position, and lacks near-term catalysts. Broader market declines also contributed to the drop. The company is working to meet NYSE listing standards.
3 min readPicard Medical Inc. (PMI) shares rose 27% after Q2 2026 revenue of $2.954M beat estimates by 90.58%, up 38.62% YoY. Despite a loss of $(3.05) per share, investors focused on top-line growth and improved gross margins. The company is investing in R&D for its next-gen Emperor Total Artificial Heart, presenting new data at conferences. PMI completed a 1-for-50 reverse stock split in July 2026 to regain NYSE compliance.
2 min readSeveral biotech stocks are trading higher in premarket, including Autonomix Medical (AMIX) up 29% at $6.92, Picard Medical (PMI) up 12% at $5.85, and others. The gains indicate early momentum and potential volatility for the trading day, according to the market activity.
1 min readPicard Medical (PMI) rose 40% after reporting Q2 revenue growth of 39% to $3.0M. Sadot Group (SDOT) surged 100% despite zero revenue, with net income up to $35.2M. Capricor Therapeutics (CAPR) gained 11% after FDA extended review for deramiocel. GRI Bio (GRI) climbed 10% with Phase 2a data selected for ERS 2026. Biomea Fusion (BMEA) rose 14% after completing Phase 2 diabetes trial enrollment. Yarrow Bioscience (YARW) advanced 12% with Graves' disease trial updates.
3 min readPicard Medical, Inc. (PMI) shares rose 40% after reporting Q2 2026 revenue growth of 39% to $3.0M, driven by U.S. sales of SynCardia products. Gross profit improved to $0.6M, and net loss narrowed by 16%. The company also advanced its Emperor Total Artificial Heart platform and completed a reverse stock split to comply with NYSE listing requirements.
2 min readPicard Medical Inc. stock surged 43.9% in pre-market trading after reporting Q2 2026 revenue of $2.95M, exceeding expectations of $1.55M. The company also issued an investor presentation. The S&P 500, Nasdaq, and Dow were down slightly, indicating the rally was company-specific.
1 min readPicard Medical reported Q2 2026 revenue growth of 39% to $3.0M, with a 16% reduction in net loss to $5.7M. Year-to-date revenue rose 50% to $4.1M, with $0.9M in gross profit. The company is advancing its Emperor Total Artificial Heart platform and focusing on operational improvements. PMI completed a 1-for-50 reverse stock split to comply with NYSE American listing standards.
2 min readPicard Medical reported a 50% revenue increase to $4.1M, driven by U.S. sales, but a wider net loss of $13.3M due to R&D and SG&A expenses. The company faces going concern risks, customer concentration, and litigation, while investing in next-gen heart tech.
1 min readNicotine pouches are gaining investor attention as cigarette sales decline, with brands like PMI's Zyn and BAT's Velo showing rapid growth and strong margins. BAT expects the global pouch market to grow from £4B in 2025 to £11B by 2030, with pouch volumes in Asia, Middle East, and Africa up 27.5% in H1 2026. PMI reported higher profitability for pouches compared to cigarettes and heated tobacco. Analysts note that pouch performance influences tobacco-company valuations, but wider adoption faces
5 min read
